Evidence map›Paper›PMID 42717093›Full record

ArticleNature2026

TRI-611, a selective, brain-penetrant molecular glue degrader of ALK.

Andrew R Conery, Daniel S La, Artyom A Alekseyenko, David Marcoux, Aaron G Bart, Matt L Harlow, Patrick R Arsenault, Nico R Cantone, Rebecca L Casaubon, Alexander Constan and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Molecular glue targets ALK resistance.Nature reviews. Drug discovery · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Andrew R Conery *Triana Biomedicines, Lexington, MA, USA. andy.conery@trianabio.com.ORCID http://orcid.org/0000-0003-3638-7633
Daniel S La *Triana Biomedicines, Lexington, MA, USA.
Artyom A AlekseyenkoTriana Biomedicines, Lexington, MA, USA.
David MarcouxTriana Biomedicines, Lexington, MA, USA.
Aaron G BartTriana Biomedicines, Lexington, MA, USA.
Matt L HarlowTriana Biomedicines, Lexington, MA, USA.
Patrick R ArsenaultTriana Biomedicines, Lexington, MA, USA.
Nico R CantoneTriana Biomedicines, Lexington, MA, USA.ORCID http://orcid.org/0000-0001-9709-8830
Rebecca L CasaubonTriana Biomedicines, Lexington, MA, USA.
Alexander ConstanTriana Biomedicines, Lexington, MA, USA.
Hari B KamaduraiTriana Biomedicines, Lexington, MA, USA.
Aravind Prasad MedikondaTriana Biomedicines, Lexington, MA, USA.
Duncan E NunesTriana Biomedicines, Lexington, MA, USA.ORCID http://orcid.org/0009-0008-3652-0282
Hannah SzetoTriana Biomedicines, Lexington, MA, USA.
Tim J WigleTriana Biomedicines, Lexington, MA, USA.
Maolin YuTriana Biomedicines, Lexington, MA, USA.
Aleksandra ZagulyaevaTriana Biomedicines, Lexington, MA, USA.
Christine M ZarateTriana Biomedicines, Lexington, MA, USA.
Lauren HighfieldMassachusetts General Hospital, Boston, MA, USA.
Nobuyuki KondoMassachusetts General Hospital, Boston, MA, USA.
Aaron N HataMassachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6127-318X
Kenneth NgoDana Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5511-2825
Jisu LeeDana Farber Cancer Institute, Boston, MA, USA.
Prafulla C GokhaleDana Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1974-5921
Caroline GermaTriana Biomedicines, Lexington, MA, USA.
Kathleen I SeybTriana Biomedicines, Lexington, MA, USA.
Patrick TrojerTriana Biomedicines, Lexington, MA, USA.
Vito J PalombellaTriana Biomedicines, Lexington, MA, USA. vito@trianabio.com.ORCID http://orcid.org/0009-0004-2939-7053

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitors (TKIs) targeting anaplastic lymphoma kinase (ALK) have transformed the treatment landscape of ALK fusion-positive non-small-cell lung carcinoma (ALK-positive NSCLC), but the limited options for patients who progress on approved TKIs highlight a continued need for an orthogonal therapeutic approach

Indexed as

Anaplastic Lymphoma KinaseBrainProtein Kinase InhibitorsProteolysisPyrimidinesAnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorDegronsFemaleHumansLung NeoplasmsMiceModels, MolecularOncogene Proteins, FusionProteolysis Targeting ChimeraALK protein, humanAnaplastic Lymphoma KinaseOncogene Proteins, FusionProtein Kinase InhibitorsProteolysis Targeting ChimeraPyrimidinesTyrosine Kinase InhibitorsUbiquitin-Protein Ligases

Identifiers

PMID42717093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.